AAAAAA

   
Results: 1-9 |
Results: 9
A pilot trial of vitaxin, a humanized anti-vitronectin receptor (anti alpha(v)beta(3)) antibody in patients with metastatic cancer
Authors: Posey, JA Khazaeli, MB DelGrosso, A Saleh, MN Lin, CY Huse, W LoBuglio, AF
Citation: Ja. Posey et al., A pilot trial of vitaxin, a humanized anti-vitronectin receptor (anti alpha(v)beta(3)) antibody in patients with metastatic cancer, CANC BIO R, 16(2), 2001, pp. 125-132
Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer
Authors: Robert, F Ezekiel, MP Spencer, SA Meredith, RF Bonner, JA Khazaeli, MB Saleh, MN Carey, D LoBuglio, AF Wheeler, RH Cooper, MR Waksal, HW
Citation: F. Robert et al., Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer, J CL ONCOL, 19(13), 2001, pp. 3234-3243
BR96-Doxorubicin: Been there, done that! In reply
Authors: Saleh, MN
Citation: Mn. Saleh, BR96-Doxorubicin: Been there, done that! In reply, J CL ONCOL, 18(23), 2000, pp. 4000-4000
Enhanced apoptosis with combination C225/radiation treatment serves as theimpetus for clinical investigation in head and neck cancers
Authors: Bonner, JA Raisch, KP Trummell, HQ Robert, F Meredith, RF Spencer, SA Buchsbaum, DJ Saleh, MN Stackhouse, MA LoBuglio, AF Peters, GE Carroll, WR Waksal, HW
Citation: Ja. Bonner et al., Enhanced apoptosis with combination C225/radiation treatment serves as theimpetus for clinical investigation in head and neck cancers, J CL ONCOL, 18(21), 2000, pp. 47S-53S
Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-Doxorubicin inpatients with Lewis Y-expressing epithelial tumors
Authors: Saleh, MN Sugarman, S Murray, J Ostroff, JB Healey, D Jones, D Daniel, CR LeBherz, D Brewer, H Onetto, N LoBuglio, AF
Citation: Mn. Saleh et al., Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-Doxorubicin inpatients with Lewis Y-expressing epithelial tumors, J CL ONCOL, 18(11), 2000, pp. 2282-2292
A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia
Authors: Saleh, MN Gutheil, J Moore, M Bunch, PW Butler, J Kunkel, L Grillo-Lopez, AJ LoBuglio, AF
Citation: Mn. Saleh et al., A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia, SEMIN ONCOL, 27(6), 2000, pp. 99-103
Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation
Authors: Saleh, MN Raisch, KP Stackhouse, MA Grizzle, WE Bonner, JA Mayo, MS Kim, HG Meredith, RF Wheeler, RH Buchsbaum, DJ
Citation: Mn. Saleh et al., Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation, CANC BIO R, 14(6), 1999, pp. 451-463
Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration
Authors: Conry, RM Khazaeli, MB Saleh, MN Allen, KO Barlow, DL Moore, SE Craig, D Arani, RB Schlom, J LoBuglio, AF
Citation: Rm. Conry et al., Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration, CLIN CANC R, 5(9), 1999, pp. 2330-2337
Diphtheria toxin fusion proteins
Authors: Foss, FM Saleh, MN Krueger, JG Nichols, JC Murphy, JR
Citation: Fm. Foss et al., Diphtheria toxin fusion proteins, CURR T MICR, 234, 1998, pp. 63-81
Risultati: 1-9 |